Spesolimab in generalised pustular psoriasis flares: a profile of its use

<div><strong>Declarations</strong></div> <div><strong>Funding</strong> The preparation of this review was not supported by any external funding.</div> <div><strong>Authorship and Conflict of interest</strong> T. Nie is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.</div> <div><strong>Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability</strong> Not applicable.</div> <p><br></p> <div>Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews" target="_blank"><strong>here</strong></a>.</div> <p><br></p> <div><strong>Abstract</strong></div> <div>Spesolimab (Spevigo^®) is a promising new treatment for generalised pustular psoriasis (GPP) flares. GPP is a rare and life-threatening autoinflammatory disease characterized by flares of widespread skin lesions with pustules, which may be accompanied by systemic inflammation. Spesolimab, a novel interleukin (IL)-36 receptor antagonist, is approved in the EU and USA for the treatment of GPP flares in adults. In a pivotal phase 2 trial, a significantly higher proportion of patients with a GPP flare who received a single intravenous dose of spesolimab had no visible pustules and clear or almost clear skin at the end of week 1 compared with placebo. These responses were sustained to 12 weeks. Spesolimab was generally well tolerated, with low incidences of the most common treatment-emergent adverse events. However, spesolimab may increase the risk of infections and may be associated with hypersensitivity and infusion-related reactions. </div> <p><br></p> <div><strong>©</strong> Springer Nature Switzerland AG 2023</div>